Indivior PLC (LON:INDV – Get Free Report) shares fell 15.7% during mid-day trading on Thursday . The company traded as low as GBX 548.71 ($6.90) and last traded at GBX 732 ($9.21). 1,888,371 shares were traded during mid-day trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.92).
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,800 ($22.65) price target on shares of Indivior in a research report on Tuesday, December 17th.
View Our Latest Analysis on INDV
Indivior Trading Down 15.7 %
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- What is Forex and How Does it Work?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Which Wall Street Analysts are the Most Accurate?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.